VAZKEPA Soft capsule Ref.[50397] Active ingredients: Eicosapentaenoic acid

Source: European Medicines Agency (EU)  Revision Year: 2022  Publisher: Amarin Pharmaceuticals Ireland Limited, 88 Harcourt Street, Dublin 2, D02DK18, Ireland

Product name and form

Vazkepa 998 mg soft capsules.

Pharmaceutical Form

Soft capsule (capsule).

Oblong soft capsule, 25 × 10 mm, printed with “IPE” in white ink, with a light yellow to amber shell containing a colourless to pale yellow liquid.

Qualitative and quantitative composition

Each capsule contains 998 mg of icosapent ethyl.

Excipients with known effect: Each capsule contains 30 mg maltitol (E965 ii), 83 mg sorbitol (E420 ii) and soya lecithin.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Eicosapentaenoic acid

Eicosapentaenoic acid (EPA; also icosapentaenoic acid) is an omega-3 fatty acid. It also has the trivial name timnodonic acid. Eicosapentaenoic acid is a polyunsaturated fatty acid (PUFA) that acts as a precursor for prostaglandin-3 (which inhibits platelet aggregation), thromboxane-3, and leukotriene-5 eicosanoids. Eicosapentaenoic acid is both a precursor and the hydrolytic breakdown product of eicosapentaenoyl ethanolamide (EPEA: C22H35NO2; 20:5,n-3).

List of Excipients

Capsule fill:

all-rac-alpha-tocopherol

Capsule shell:

Gelatin
Glycerol
Liquid maltitol (E965 ii)
Liquid sorbitol (non-crystallising) (E420 ii)
Purified water
Soya lecithin

Printing ink:

Titanium dioxide
Propylene glycol
Hypromellose

Pack sizes and marketing

High density polyethylene (HDPE) bottles with a child-resistant polypropylene heat induction sealed closure containing 120 soft capsules.

Pack size of one bottle or three bottles per carton.

PVC/PCTFE/Al perforated unit dose blisters containing 4x2 soft capsules.

Not all pack sizes may be marketed.

Marketing authorization holder

Amarin Pharmaceuticals Ireland Limited, 88 Harcourt Street, Dublin 2, D02DK18, Ireland

Marketing authorization dates and numbers

EU/1/20/1524/001
EU/1/20/1524/002
EU/1/20/1524/003

Date of first authorisation: 26 March 2021

Drugs

Drug Countries
VAZKEPA Austria, Estonia, France, Croatia, Ireland, Israel, Italy, Lithuania, Poland, Romania, United Kingdom

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.